文献速递神经核医学肿瘤 PET/CT

[18F]FDG PET在检测早期tau相关神经退行性变方面优于MRI

[18F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-20

结果显示,颞顶区低代谢在早期/中期Braak分期即可检出且效应量大,而MRI灰质萎缩效应较小且仅在晚期显著;跨模态比较证实多数受累区低代谢比灰质萎缩更明显。

要点

  • [18F]FDG PET低代谢在早期/中期Braak分期即可检出,且效应量大
  • MRI灰质萎缩效应较小,仅在晚期Braak分期显著
  • 多数受累脑区低代谢比灰质萎缩更明显,更贴近tau病理

核心结论

  • [18F]FDG PET低代谢是AD相关神经退行性变的敏感且早期标志物,先于MRI可检出的灰质萎缩,并在各疾病阶段更贴近潜在tau病理。

研究设计与样本

  • 对显著相关脑区进一步比较早期/中期(II-IV期;n=24)与晚期(V/VI期;n=56)Braak分期相对对照(0/I期;n=8)的差异。
  • 因病理对照组样本量有限,分析在45例年龄匹配、PET无淀粉样蛋白或tau病理证据的认知未受损个体中重复验证。

主要发现

  • 较高Braak分期与颞顶区[18F]FDG PET低代谢相关,早期/中期即可检出大效应,晚期进一步减低。
  • 同期MRI灰质萎缩呈相似但较小的效应,仅在晚期Braak分期显著。
  • 跨模态直接比较证实多数受累区低代谢比灰质萎缩更明显。
  • 在较大认知未受损对照样本中重复分析获得高度相似的结果。

临床怎么用

  • [18F]FDG PET可用于AD相关神经退行性变的早期检测,在MRI灰质萎缩尚不明显时提示tau相关神经退行性变。
  • 结果支持将[18F]FDG PET低代谢作为跨疾病阶段反映tau病理的敏感影像标志物。

局限性

  • 病理对照组仅8例,样本量有限,故采用较大认知未受损样本进行重复验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neurodegeneration is a hallmark of Alzheimer's disease (AD), measurable in-vivo with [18F]FDG PET or MRI. However, the relative sensitivities of these modalities at different stages of AD remain poorly understood. Here, we directly compared associations of hypometabolism and gray matter (GM) atrophy with tau pathology staging at autopsy. METHODS: Eighty-eight individuals from the ADNI autopsy cohort with Braak tau staging and ante-mortem [18F]FDG PET and T1-weighted MRI scans were analyzed. Spearman correlations assessed associations between Braak stage and hypometabolism or GM atrophy across 52 regions of interest. Regions showing significant correlations were further assessed for differences between early/intermediate (II-IV; n=24) and advanced (V/VI, n=56) Braak stages compared to controls (0/I, n=8). To address the limited size of the pathological control group, analyses were replicated using a larger sample of age-matched cognitively unimpaired individuals with no evidence of amyloid or tau pathology on PET imaging (n=45). RESULTS: Higher Braak stages were associated with [18F]FDG PET hypometabolism in temporo-parietal regions, with large effects detectable even at early/intermediate stages and further reductions in advanced stages. Concomitant MRI-derived GM atrophy showed similar but smaller effects, significant only for advanced stages. Direct cross-modality comparisons confirmed more pronounced hypometabolism than GM atrophy across most affected regions. Replication analyses using the larger cognitively unimpaired control sample yielded highly similar findings. CONCLUSION: [18F]FDG PET hypometabolism is a sensitive and early marker of AD-related neurodegeneration, preceding MRI-detectable GM atrophy and more closely reflecting underlying tau pathology across disease stages.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Vourkas O, Zhang L, Jimenez-Pérez A, et al. [18F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration. Eur J Nucl Med Mol Imaging. 2026. PMID: 42474503. doi:10.1007/s00259-026-08093-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。